ClinicalTrials.gg
CompletedNCT03189524Updated Dec 27, 2024Results posted

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

A Phase 1 interventional study of Zanubrutinib in B-cell Lymphoma, sponsored by BeiGene. Completed at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2016, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Enrollment
103rd of 273
44 · median 30
Started
2016
with 13 others
Phase 1
124 of 283
57 open now
Registered
31st of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 103rd largest by enrollment of the 273 interventional ones that give a count, is one of 14 that started in 2016, is one of 124 in phase 1, and was the 31st registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by conducting in two stages, the first stage being the safety assessment of dose and the second stage being the dose expansion.

Part I: Safety evaluation - according to the results of preclinical toxicological trials and the results of the phase I clinical study conducted in Australia and New Zealand, two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]), administered in the morning and at night, or 320 mg once daily [QD]) and "3+3" design was adopted for the assessment. The recommended dose and method of administration of the phase II clinical study was determined according to the Part I results.

Part II: Dose expansion - this stage was to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL), approximately 20 participants with relapsed or refractory FL or MZL were to be enrolled. The recommended Phase 2 dose (RP2D) was used in Part II.

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and women between the age of 18-75 years.
  • Participants with B-cell lymphoma (defined by World Health Organization classification) or relapsed following at least one .
  • Judged by the investigator as requiring treatment.
  • performance status of 0-1.
  • of at least 4 months.
  • Adequate hematological function.
  • Adequate renal function.
  • Adequate liver function.
  • Adequate coagulation function.
  • Female participants of and non-sterile males must have practiced at least one of the following methods of with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
  • Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment.

Key Exclusion Criteria:

  • With central nervous system involvement of the disease.
  • The pathological type of the disease had disease transformation.
  • Had underdone hematopoietic stem cell transplantation.
  • Had received anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
  • Had received BTK inhibitor treatment prior to enrollment.
  • Had received chemotherapy and has not yet recovered from toxicity
  • Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
  • History of other within 2 years before study.
  • With uncontrolled systemic infection.
  • Major surgery in the past 4 weeks.
  • With known , or active or virus infection.
  • With cardiovascular disease of Classification ≥ 3.
  • Significant abnormalities.
  • Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
  • Inability to comply with study procedures.
  • Was currently taking anticoagulant drugs.
  • Was currently taking potent cytochrome P450 3A inhibitor or inducer.
  • Had stroke or cerebral hemorrhage within 6 months before enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Part I: 160 mg BID

    Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily \[BID\]) administered in the morning and at night, or 320 mg (once daily \[QD\]), and a "3+3" design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D).

    Drug: Zanubrutinib

  • Experimental
    Part I: 320 mg QD

    Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a "3+3" design was adopted for Part I of the study to determine RP2D.

    Drug: Zanubrutinib

  • Experimental
    Part II: 160 mg BID

    Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).

    Drug: Zanubrutinib

Interventions

  • Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.

    Also known as: BGB-3111

06

What researchers measure

Primary outcomes

  1. Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

    All adverse events were treatment emergent and were defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03) grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)

  2. Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL

    Overall response in overall response rate (ORR) was defined as a participant's best overall response: CR or PR for NHL participants; CR, complete remission with incomplete blood count recovery, nodular PR, PR, or PR with lymphocytosis for the CLL participants; CR, very good PR, PR, or minor response for the Waldenström macroglobulinemia participants. ORR was defined as the percentage of participants who achieved an overall response.

    Time frame: Up to 4 years and 1 month

  3. Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL

    CRR was defined as the percentage of participants who achieved CR as the best overall response.

    Time frame: Up to 4 years and 1 month

  4. Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL

    PRR was defined as the percentage of participants who achieved PR or higher as the best overall response.

    Time frame: Up to 4 years and 1 month

  5. Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL

    Duration of response for responders (those who achieved an overall response of PR or better) was defined as the time interval (in number of days) between the date of the earliest qualifying response and the date of progressive disease or death for any cause (whichever occurs earlier). Duration of response analysis included only responders.

    Time frame: Up to 4 years and 1 month

  6. Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL

    Progression-free survival was defined as the time (in months) from the date of first study treatment to disease progression or death (due to any cause), whichever occurred first. For purposes of calculating PFS, the start date of progressive disease was the date at which progression was first observed. The duration and primary analysis of PFS was right-censored for participants who met 1 of the following conditions: 1) no baseline disease assessments; 2) starting a new anticancer therapy before documentation of disease progression or death; 3) death or disease progression immediately after more than 1 consecutively missed disease assessment visit; and 4) alive without documentation of disease progression before the data cutoff date.

    Time frame: Up to 4 years and 1 month

Secondary outcomes

  1. Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  2. Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  3. Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  4. Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  5. Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  6. Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  7. Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  8. Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  9. Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  10. Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib

    Time frame: Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

  11. Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib

    The percentage of BTK occupied in peripheral blood mononuclear cells was evaluated as a biomarker for the inhibition of BTK on specified days and the average value is reported.

    Time frame: DLT Period: Days 1 and 2 of Week 1 and Day 1 of Week 2

  12. Part II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

    All adverse events are treatment emergent, defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the NCI-CTCAE v4.03 grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)

07

Results

Posted Oct 22, 2021

Participant flow

This study was conducted at 4 centers in China, all of which enrolled participants. The first participant was dosed on 05 July 2016. As of the final database lock (15 October 2020), 44 participants were enrolled and treated with zanubrutinib (BGB-3111). Once the final analysis was completed, the study was terminated and all participants who were still on treatment were transferred to long term extension study.

Participant flow — Overall Study
MilestonePart I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BID
Started111023
Received at least 1 dose of study drug111023
Completed000
Not completed111023
Withdrew: Study terminated by sponsor after final analysis and all remaining participants transferred to lte7511
Withdrew: Death221
Withdrew: Lost to follow-up108
Withdrew: Withdrawal by subject113
Withdrew: Progressive disease020

Outcome measures

PrimaryPart I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

All adverse events were treatment emergent and were defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03) grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)
Reported as:
Count of participants · Participants
Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events
ParticipantsPart I: 160 mg BIDPart I: 320 mg QD
Participants with ≥ 1 adverse event1110
Participants with serious adverse events22
PrimaryPart II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL

Overall response in overall response rate (ORR) was defined as a participant's best overall response: CR or PR for NHL participants; CR, complete remission with incomplete blood count recovery, nodular PR, PR, or PR with lymphocytosis for the CLL participants; CR, very good PR, PR, or minor response for the Waldenström macroglobulinemia participants. ORR was defined as the percentage of participants who achieved an overall response.

Time frame:
Up to 4 years and 1 month
Reported as:
Number · Percentage of Participants
Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL
Percentage of ParticipantsPart II: 160 mg BID
Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL30.4 (13.2 to 52.9)
PrimaryPart II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL

CRR was defined as the percentage of participants who achieved CR as the best overall response.

Time frame:
Up to 4 years and 1 month
Reported as:
Number · Percentage of Participants
Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL
Percentage of ParticipantsPart II: 160 mg BID
Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL13 (2.8 to 33.6)
PrimaryPart II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL

PRR was defined as the percentage of participants who achieved PR or higher as the best overall response.

Time frame:
Up to 4 years and 1 month
Reported as:
Number · Percentage of Participants
Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL
Percentage of ParticipantsPart II: 160 mg BID
Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL30.4 (13.2 to 52.9)
PrimaryPart II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL

Duration of response for responders (those who achieved an overall response of PR or better) was defined as the time interval (in number of days) between the date of the earliest qualifying response and the date of progressive disease or death for any cause (whichever occurs earlier). Duration of response analysis included only responders.

Time frame:
Up to 4 years and 1 month
Reported as:
Median · Months
Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL
MonthsPart II: 160 mg BID
Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL11.2 (2.8 to NA)
PrimaryPart II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL

Progression-free survival was defined as the time (in months) from the date of first study treatment to disease progression or death (due to any cause), whichever occurred first. For purposes of calculating PFS, the start date of progressive disease was the date at which progression was first observed. The duration and primary analysis of PFS was right-censored for participants who met 1 of the following conditions: 1) no baseline disease assessments; 2) starting a new anticancer therapy before documentation of disease progression or death; 3) death or disease progression immediately after more than 1 consecutively missed disease assessment visit; and 4) alive without documentation of disease progression before the data cutoff date.

Time frame:
Up to 4 years and 1 month
Reported as:
Median · Months
Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL
MonthsPart II: 160 mg BID
Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL5.5 (4.6 to 16.4)
SecondaryPart I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · nanogram/milliliter*hour
Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib
nanogram/milliliter*hour160 mg BID320 mg QD
Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib981.6 ± 619.61404 ± 560.7
SecondaryPart I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · nanogram/milliliter*hour
Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib
nanogram/milliliter*hour160 mg BID320 mg QD
Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib1025 ± 633.51537 ± 519.0
SecondaryPart I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · nanogram/milliliter
Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib
nanogram/milliliter160 mg BID320 mg QD
Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib319 ± 217409 ± 149
SecondaryPart I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Median · hour
Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib
hour160 mg BID320 mg QD
Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib2.00 (0.42 to 5.98)2.50 (1.00 to 4.00)
SecondaryPart I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · hour
Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib
hour160 mg BID320 mg QD
Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib2.27 ± 1.213.43 ± 2.23
SecondaryPart I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · liter/hour
Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib
liter/hour160 mg BID320 mg QD
Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib251 ± 194235 ± 93.7
SecondaryPart I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · liter
Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib
liter160 mg320 mg QD
Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib713 ± 5121120 ± 738
SecondaryPart I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · nanogram/milliliter*hour
Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib
nanogram/milliliter*hour160 mg BID320 mg QD
Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib738.3 ± 425.21277 ± 607.4
SecondaryPart I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Mean · nanogram/milliliter
Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib
nanogram/milliliter160 mg BID320 mg QD
Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib257 ± 147389 ± 185
SecondaryPart I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib
Time frame:
Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose
Reported as:
Median · hour
Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib
hour160 mg BID320 mg QD
Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib2.00 (0.43 to 2.93)2.0 (1.00 to 3.27)
SecondaryPart I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib

The percentage of BTK occupied in peripheral blood mononuclear cells was evaluated as a biomarker for the inhibition of BTK on specified days and the average value is reported.

Time frame:
DLT Period: Days 1 and 2 of Week 1 and Day 1 of Week 2
Reported as:
Mean · Percentage
Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib
PercentagePart I: 160 mg BID or 320 mg QD
Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib96.69 ± 5.297
SecondaryPart II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

All adverse events are treatment emergent, defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the NCI-CTCAE v4.03 grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)
Reported as:
Count of participants · Participants
Part II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events
ParticipantsPart II: 160 mg BID
Participants with ≥ 1 adverse event22
Participants with serious adverse events5

Adverse events

Collected over From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part I: 160 mg BID2/11 (18.2%)2/11 (18.2%)11/11 (100%)
Part I: 320 mg QD3/10 (30%)2/10 (20%)10/10 (100%)
Part II: 160 mg BID1/23 (4.3%)5/23 (21.7%)22/23 (95.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPart I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BID
Febrile neutropeniaBlood and lymphatic system disorders0/111/100/23
Neutrophil count decreasedInvestigations0/111/100/23
Platelet count decreasedInvestigations0/111/100/23
Cholesterin granuloma of middle earNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/110/100/23
Toxic epidermal necrolysisSkin and subcutaneous tissue disorders1/110/100/23
AnaemiaBlood and lymphatic system disorders0/110/101/23
LymphadenopathyBlood and lymphatic system disorders0/110/101/23
AscitesGastrointestinal disorders0/110/101/23
FatigueGeneral disorders0/110/101/23
Pleural infectionInfections and infestations0/110/101/23
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPart I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BID
Neutrophil count decreasedInvestigations8/117/109/23
Upper respiratory tract infectionInfections and infestations5/115/105/23
NasopharyngitisInfections and infestations5/111/100/23
AnaemiaBlood and lymphatic system disorders4/114/108/23
White blood cell count decreasedInvestigations3/113/109/23
Platelet count decreasedInvestigations4/112/104/23
HaematuriaRenal and urinary disorders4/113/102/23
Weight increasedInvestigations2/113/103/23
PneumoniaInfections and infestations3/113/103/23
Rash maculo-papularSkin and subcutaneous tissue disorders2/113/100/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BIDTotal
Mean51.9 ± 10.6552.1 ± 10.5748.4 ± 11.8550.1 ± 11.18
Sex: Female, Male
Sex: Female, Male(Participants)Part I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BIDTotal
Female231520
Male97824
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part I: 160 mg BIDPart I: 320 mg QDPart II: 160 mg BIDTotal
American Indian or Alaska Native0000
Asian11102344
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

4 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
09

References and documents

Publications

  • Jun Zhu, BS, Jianyong Li, MD, Jianfeng Zhou, Yuqin Song, MD, Junyuan Qi, Wei Xu, Dengju Li, MD, Mingyuan Sun, Ling Xue, PhD, Liudi Yang, Yinwei Zhang, Lai Wang, PhD, Jane Huang, MD, Shibao Feng, PhD, Lugui Qiu, MD. BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 2017; 130(1): 5347. https://doi.org/10.1182/blood.V130.Suppl_1.5347.5347
  • Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7. Epub 2022 Jul 28. PubMed 35900694 ↗
  • Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J. A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. Br J Haematol. 2022 Jul;198(1):62-72. doi: 10.1111/bjh.18162. Epub 2022 Apr 5. PubMed 35383885 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Aug 2020, 49 months.

Results were first posted in Oct 2021, 1 year 1 month after primary completion.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 49 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 16, 2017
StartActual
Jul 5, 2016
Primary completionActual
Aug 26, 2020
CompletionActual
Aug 26, 2020
Results first posted
Oct 22, 2021
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03189524
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jun 16, 2017
Start date
Jul 5, 2016
Primary completion
Aug 26, 2020
Completion
Aug 26, 2020
Results posted
Oct 22, 2021
Last update
Dec 27, 2024

Study contacts

Study Director
principal investigator · BeiGene
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion